McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219 (2011).

Article  CAS  PubMed  Google Scholar 

Gravallese, E. M. & Firestein, G. S. Rheumatoid arthritis—common origins, divergent mechanisms. N. Engl. J. Med. 388, 529–542 (2023).

Article  CAS  PubMed  Google Scholar 

Malmström, V., Catrina, A. I. & Klareskog, L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat. Rev. Immunol. 17, 60–75 (2016).

Article  PubMed  Google Scholar 

Humby, F. et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 6, 59–75 (2009).

Article  Google Scholar 

Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572–2581 (2004).

Article  CAS  PubMed  Google Scholar 

Buch, M. H. Defining refractory rheumatoid arthritis. Ann. Rheum. Dis. 77, 966–969 (2018).

Article  CAS  PubMed  Google Scholar 

Rivellese, F. et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat. Med. 28, 1256–1268 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907–1915 (2003).

Article  CAS  PubMed  Google Scholar 

Goebeler, M. E. & Bargou, R. C. T cell-engaging therapies—BiTEs and beyond. Nat. Rev. Clin. Oncol. 17, 418–434 (2020).

Article  PubMed  Google Scholar 

Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836–847 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gruen, M., Bommert, K. & Bargou, R. C. T-cell-mediated lysis of B cells induced by a CD19×CD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol. Immunother. 53, 625–632 (2004).

Article  CAS  PubMed  Google Scholar 

Loffler, A. et al. A recombinant bispecific single-chain antibody, CD19×CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098–2103 (2000).

Article  CAS  PubMed  Google Scholar 

Hoffmann, P. et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J. Cancer 115, 98–104 (2005).

Article  CAS  PubMed  Google Scholar 

Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P. & Baeuerle, P. A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 43, 763–771 (2006).

Article  CAS  PubMed  Google Scholar 

Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974–977 (2008).

Article  CAS  PubMed  Google Scholar 

Topp, M. S. et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493–2498 (2011).

Article  CAS  PubMed  Google Scholar 

Vos, K. et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 56, 772–778 (2007).

Article  CAS  PubMed  Google Scholar 

Schett, G., Tanaka, Y. & Isaacs, J. D. Why remission is not enough: underlying disease mechanisms in RA that prevent cure. Nat. Rev. Rheumatol. 17, 135–144 (2021).

Article  PubMed  Google Scholar 

Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353, 1114–1123 (2005).

Article  CAS  PubMed  Google Scholar 

Jois, R. N., Masding, A., Somerville, M., Gaffney, K. & Scott, D. G. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience. Rheumatol. (Oxf.) 46, 980–982 (2007).

Article  CAS  Google Scholar 

Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567–569 (2021).

Article  PubMed  Google Scholar 

Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124–2132 (2022).

Article  CAS  PubMed  Google Scholar 

Bergmann, C. et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann. Rheum. Dis. 82, 1117–1120 (2023).

Article  PubMed  Google Scholar 

Muller, F. et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401, 815–818 (2023).

Article  PubMed  Google Scholar 

Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N. Engl. J. Med. 390, 687–700 (2024).

Article  PubMed  Google Scholar 

Hutchings, M. et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet 398, 1157–1169 (2021).

Article  CAS  PubMed  Google Scholar 

Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lesokhin, A. M. et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat. Med. 29, 2259–2267 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taubmann, J. et al. Chimeric antigen receptor T cell treatment: unraveling the role of B cells in systemic lupus erythematosus. Arthritis Rheumatol. 76, 497–504 (2024).

Teachey, D. T. et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154–5157 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580–1588 (2010).

Article  PubMed  Google Scholar 

Wells, G. et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann. Rheum. Dis. 68, 954–960 (2009).

Article  CAS  PubMed  Google Scholar 

D’Agostino, M. A. et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: definition and development of a standardised, consensus-based scoring system. RMD Open 3, e000428 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Kuwert, T., Schmidkonz, C., Prante, O., Schett, G. & Ramming, A. FAPI PET opens a new window to understanding immune-mediated inflammatory diseases. J. Nucl. Med. 63, 1136–1137 (2022).

Article  PubMed  Google Scholar 

Alivernini, S. et al. Inclusion of synovial tissue-derived characteristics in a nomogram for the prediction of treatment response in treatment-naive rheumatoid arthritis patients. Arthritis Rheumatol. 73, 1601–1613 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krenn, V. et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology 49, 358–364 (2006).

Article  CAS  PubMed  Google Scholar